Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Suicide is a major public health concern and a leading cause of death in most societies.
Suicidal behaviour is complex and heterogeneous, likely resulting from several causes. It …

Ketamine has been demonstrated to be a rapid-onset and long-lasting antidepressant, but
its underlying molecular mechanisms remain unclear. Recent studies have emerged …

The exposure to stressful experiences during the prenatal period and through the first years
of life is known to affect the brain developmental trajectories, leading to an enhanced …

Conventional antidepressants that target monoaminergic receptors require several weeks to
be efficacious. This lag represents a significant problem in the currently available treatments …

Ketamine is considered a dissociative anesthetic medication, and it is commonly
administered by a parenteral route. It works mainly by blocking the N-methyl-D-aspartate …

Numerous studies have demonstrated the antidepressant effects of group II metabotropic
glutamate (mGlu2/3) receptor antagonists in various rodent models. Importantly, it has been …

Background: Bipolar disorder (BD) is a debilitating mental ailment characterized by recurrent
episodes of mania and depression. Primary mood-stabilizing drugs like lithium and …

Increasing evidence indicates that dysfunction of glutamate receptors is involved in the
pathophysiology of major depressive disorder (MDD). Although accumulating efforts have …

Despite the hardships of major depressive disorder (MDD), biomarkers for the diagnosis and
pharmacological management of this condition are lacking. MicroRNAs are epigenetic …